Pain medications for chronic conditions are making it on the list of the most frequently used drugs for some health plans.
PAIN MEDICATIONS for chronic conditions are making it on the list of most frequently used drugs for some health plans. And as utilization increases, so does the potential for abuse. The number of Americans seeking treatment for addiction to prescription pain medications increased 400% just over the last decade.
That should be warning for payers and other stakeholders to jump-start programs that manage opioid use, such as fill monitoring and medication use agreements signed by the patient and physician.
"Oxycontin and hydrocodone are replacing cocaine and heroin as the most popular street drugs," says Martin Burruano, director, pharmacy services for Independent Health in Buffalo, N.Y.
"Physicians are not always aware of the utilization of pain medications by their patients," says Nivedita Kohli, clinical pharmacist for Independent Health.
Physician tools include a written medication contract asking patients to voluntarily agree to obtain pain medications from only one source and to be available for random urine screenings. Burruano says that the strategy has been able to reduce the use of the combination drug by 8% since 2007.
Independent Health has a few other best practices: placing longer-acting pain medications on tier two of its formulary to encourage use; prior authorization; a registry online for physicians to review their patients' opioid use; and sponsorship of a pain medication education course for primary care physicians, pharmacists and mid-level practitioners. The first course covered prescribing safety measures, behavioral health issues related to self-care and legal implications of prescribing opiates.
The health plan also participated in the Drug Enforcement Agency (DEA) Prescription Drug Take-Back program and successfully hauled off 25,000 units of opioids.
Aetna Pharmacy Management, a pharmacy benefits manager (PBM), kicked off Aetna Rx Check Patient Safety nearly a year ago and added enhancements in October. The program analyzes prescription drug claims and identifies individuals who are being treated for opioid addiction with buprenorphine, but continue to receive prescriptions for pain medications such as Oxycontin. Taking the two drugs at the same time may cause a dangerous interaction.
A rapid retrospective claims engine analyzes members' prescription drug claims and identifies opportunities to improve care and prevent misuse, according to Robert Gregory, head of clinical programs for the PBM. Once a problem is detected, Aetna Rx Check reaches out to physicians to alert them to a possible drug-to-drug interaction, duplication in drug therapy or other serious issues. Aetna invites prescribers to ask questions about appropriate prescribing.
Its controlled substance use program separately identifies patients who are taking multiple pain medications and using multiple pharmacies and prescribers.
Gregory says anecdotally that the program has reduced the number of members identified with simultaneous use of pain medications.
"We want to ensure that we don't place barriers in front of members seeking addiction therapy, while also preventing ongoing abuse," he says.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
What Payers Need to Know As Retail Pharmacies Move Into Primary Care
September 6th 2023Healthcare beyond the doors of the doctor’s office has the potential to offer more care to more people. But payers need to think about how to ensure that care is consistent. Regardless of the setting, care decisions must be based on evidence-based content and supported with strong patient education.
Read More